Routine use of microaxial flow pump support in women with ST-elevation myocardial infarction (STEMI) related cardiogenic shock failed to demonstrate the same mortality rate decrease observed in men, though younger patients showed comparable treatment effects regardless of sex, according to a prespecified secondary analysis of the landmark DanGer Shock trial.